Cardiovascular Catch-Up: TAVR Withstands Delta Virus So Far; Stereotaxis Robot Succeeds In Trial

The impact of the Delta variant of COVID-19 on procedure volumes remains a major concern for transcatheter valve makers, Abbott launches a new PFO closure device, and more highlights from the cardiovascular technology market in early October.

Anatomy of Human Heart
• Source: Shutterstock

Despite the onset of the Delta variant of COVID-19 and widespread hospital staffing shortages, the volume of transcatheter aortic valve replacements (TAVR) in the US grew about 1% in the third quarter compared to the second quarter of 2021, according to a new report from SVB Leerink.

SVB Leerink commissioned a survey of 10 physicians performing TAVR procedures to find out how COVID-19 has ultimately affected the TAVR “referral chain” of patients

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiology

More from Device Area